NS101 IV infusion

DRUG2 trials

Sponsors

Neuracle Science Co., LTD., Hee-Jin Kim

Conditions

Dementia FrontotemporalNeurodegenerative Diseases

Phase 1

A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

CompletedNCT05143463

Neuracle Science Co., LTD.Neurodegenerative Diseases

Start: 2021-11-04End: 2022-12-22Updated: 2022-12-23

Phase 2

Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

Not yet recruitingNCT07154485

Hee-Jin KimDementia Frontotemporal

Start: 2025-10-01End: 2028-08-01Target: 15Updated: 2025-09-04

Related Papers

Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer’s disease

Alzheimer s Research & Therapy2025-07-212 citations